Scholarlink

Background <p>Antemortem plasma and structural MRI biomarkers of Alzheimer’s disease (AD) are increasingly utilized for diagnosis and prognosis but their ability to predict regional tau burden remains relatively unexplored. We aimed to evaluate predictive models based on antemortem AD plasma and structural MRI for prediction of regional tau pathology in postmortem brain tissue.</p> Methods <p>Autopsy data from 62 participants in the Mayo Clinic Study of Aging (MCSA) were analyzed (mean age of 84.6&#xa0;years; 32% female; 1.4&#xa0;years of mean time of last plasma draw to death). Tau pathology in the hippocampus and parietal cortex was quantified using two immunohistochemical markers: AT8, an early tangle maturity marker, and 2E9, an advanced tangle maturity marker. Three antemortem plasma markers including phosphorylated tau protein at threonine 181 (p-tau181), total amyloid-β (Aβ) 42 relative to Aβ40 ratio (Aβ42/40), and glial fibrillary acidic protein (GFAP) and three regional structural MRI markers including the hippocampus volume adjusted for total intracranial volume (HVA), parietal thickness (PTH) and parietal volume divided by total intracranial volume (PVTIV) were utilized as predictors. Weighted linear regression models using weights based on time from last plasma draw to death were adjusted for age, sex and cardiovascular and metabolic conditions (CMC) score for patients. We report estimated adjusted R<sup>2</sup> and partial R<sup>2</sup> for predicting postmortem tau pathology in the hippocampus and parietal cortex stained by AT8 and 2E9.</p> Results <p>MRI models (adjusted R<sup>2</sup> of 0.28–0.66) showed better performance at predicting tau pathology than plasma models (adjusted R<sup>2</sup> of 0.19–0.36). The highest adjusted R<sup>2</sup> was 0.66 for predicting hippocampal 2E9 using HVA, followed by an adjusted R<sup>2</sup> of 0.6 for hippocampal AT8. Predictions for parietal AT8 and 2E9 were lower with an adjusted R<sup>2</sup> of 0.28–0.29 based on MRI biomarkers and 0.24–0.36 based on plasma biomarkers. The adjusted R<sup>2</sup> values for both regions were higher for AT8 compared to 2E9 prediction for plasma biomarker models.</p> Conclusions <p>Our study demonstrates the greater sensitivity of regional MRI to tau pathology in comparison to plasma biomarkers. Future studies should explore newer MRI methods and additional plasma biomarkers more specific to tau pathology such as microtubule binding region for prediction of antemortem tau pathology.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association between antemortem plasma and structural MRI biomarkers and postmortem tau pathology in the Mayo Clinic Study of Aging

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月14日

查看全文
  • Mingzhao Hu,
  • Christina M. Moloney,
  • Scott A. Przybelski,
  • Alicia Algeciras-Schimnich,
  • Terry M. Therneau,
  • Angela J. Fought,
  • Darren M. Rothberg,
  • Aivi T. Nguyen,
  • R. Ross Reichard,
  • Dennis W. Dickson,
  • David S. Knopman,
  • Clifford R. Jack Jr.,
  • Ronald C. Petersen,
  • Ekaterina Hofrenning,
  • Michelle M. Mielke,
  • Jonathan Graff-Radford,
  • Melissa E. Murray,
  • Prashanthi Vemuri

摘要

Background

Antemortem plasma and structural MRI biomarkers of Alzheimer’s disease (AD) are increasingly utilized for diagnosis and prognosis but their ability to predict regional tau burden remains relatively unexplored. We aimed to evaluate predictive models based on antemortem AD plasma and structural MRI for prediction of regional tau pathology in postmortem brain tissue.

Methods

Autopsy data from 62 participants in the Mayo Clinic Study of Aging (MCSA) were analyzed (mean age of 84.6 years; 32% female; 1.4 years of mean time of last plasma draw to death). Tau pathology in the hippocampus and parietal cortex was quantified using two immunohistochemical markers: AT8, an early tangle maturity marker, and 2E9, an advanced tangle maturity marker. Three antemortem plasma markers including phosphorylated tau protein at threonine 181 (p-tau181), total amyloid-β (Aβ) 42 relative to Aβ40 ratio (Aβ42/40), and glial fibrillary acidic protein (GFAP) and three regional structural MRI markers including the hippocampus volume adjusted for total intracranial volume (HVA), parietal thickness (PTH) and parietal volume divided by total intracranial volume (PVTIV) were utilized as predictors. Weighted linear regression models using weights based on time from last plasma draw to death were adjusted for age, sex and cardiovascular and metabolic conditions (CMC) score for patients. We report estimated adjusted R2 and partial R2 for predicting postmortem tau pathology in the hippocampus and parietal cortex stained by AT8 and 2E9.

Results

MRI models (adjusted R2 of 0.28–0.66) showed better performance at predicting tau pathology than plasma models (adjusted R2 of 0.19–0.36). The highest adjusted R2 was 0.66 for predicting hippocampal 2E9 using HVA, followed by an adjusted R2 of 0.6 for hippocampal AT8. Predictions for parietal AT8 and 2E9 were lower with an adjusted R2 of 0.28–0.29 based on MRI biomarkers and 0.24–0.36 based on plasma biomarkers. The adjusted R2 values for both regions were higher for AT8 compared to 2E9 prediction for plasma biomarker models.

Conclusions

Our study demonstrates the greater sensitivity of regional MRI to tau pathology in comparison to plasma biomarkers. Future studies should explore newer MRI methods and additional plasma biomarkers more specific to tau pathology such as microtubule binding region for prediction of antemortem tau pathology.